Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PRTA -Prothena Corporation plc

Prothena Corporation plc
PRTA
$6.81
Name : Prothena Corporation plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $366,561,856.00
EPSttm : -2.05
finviz dynamic chart for PRTA
Prothena Corporation plc
$6.81
0.87%
$0.06

Float Short %

11.24

Margin Of Safety %

Put/Call OI Ratio

0.95

EPS Next Q Diff

0.24

EPS Last/This Y

-2.27

EPS This/Next Y

2.2

Price

6.81

Target Price

24.29

Analyst Recom

2.12

Performance Q

-21.9

Relative Volume

0.48

Beta

-0.03

Ticker: PRTA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04PRTA6.430.860.8523558
2025-07-07PRTA6.280.870.4323709
2025-07-08PRTA6.520.8720.7923735
2025-07-09PRTA6.570.953.0324808
2025-07-10PRTA6.580.950.3724918
2025-07-11PRTA6.390.950.6425203
2025-07-14PRTA6.430.940.0325351
2025-07-15PRTA6.220.911.9026128
2025-07-16PRTA6.340.930.0226399
2025-07-17PRTA6.490.930.6726381
2025-07-18PRTA6.280.920.0826380
2025-07-21PRTA6.291.040.0823264
2025-07-22PRTA6.540.980.1924060
2025-07-23PRTA6.760.931.6624572
2025-07-24PRTA6.70.960.2025162
2025-07-25PRTA6.680.950.3925241
2025-07-28PRTA6.880.950.0725398
2025-07-29PRTA6.930.940.2625531
2025-07-30PRTA6.860.941.1525623
2025-07-31PRTA6.880.941.2625742
2025-08-01PRTA6.80.952.5026988
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04PRTA6.43-246.7- -4.54
2025-07-07PRTA6.28-246.7- -4.54
2025-07-08PRTA6.52-246.7- -4.54
2025-07-09PRTA6.58-246.7- -4.54
2025-07-10PRTA6.57-246.7- -4.54
2025-07-11PRTA6.40-246.7- -4.54
2025-07-14PRTA6.43-246.7- -4.54
2025-07-15PRTA6.22-246.7- -4.54
2025-07-16PRTA6.34-246.7- -4.54
2025-07-17PRTA6.47-246.7- -4.54
2025-07-18PRTA6.28-246.7- -4.54
2025-07-21PRTA6.30-246.7- -4.54
2025-07-22PRTA6.54-246.7- -4.54
2025-07-23PRTA6.76-246.7- -4.54
2025-07-24PRTA6.70-246.7- -4.54
2025-07-25PRTA6.68-246.7- -4.54
2025-07-28PRTA6.84-246.7- -4.54
2025-07-29PRTA6.93-246.7- -4.54
2025-07-30PRTA6.88-246.7- -4.54
2025-07-31PRTA6.87-246.7- -4.54
2025-08-01PRTA6.81-246.7- -4.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04PRTA-34.54-29.3511.00
2025-07-07PRTA-34.54-29.3011.00
2025-07-08PRTA-34.54-29.3011.00
2025-07-09PRTA-34.54-29.3011.00
2025-07-10PRTA-34.54-29.3011.00
2025-07-11PRTA-34.54-29.3010.23
2025-07-14PRTA-34.54-29.2510.23
2025-07-15PRTA-34.54-29.2510.23
2025-07-16PRTA-34.54-29.2510.23
2025-07-17PRTA-34.54-29.2510.23
2025-07-18PRTA-34.54-29.2510.23
2025-07-21PRTA-34.54-29.1410.23
2025-07-22PRTA-34.54-29.1410.23
2025-07-23PRTA-34.54-29.1410.23
2025-07-24PRTA-34.54-29.1410.23
2025-07-25PRTA-34.54-29.1411.24
2025-07-28PRTA-34.54-28.9211.24
2025-07-29PRTA-34.54-28.9211.24
2025-07-30PRTA-34.54-28.9211.24
2025-07-31PRTA-34.54-28.9211.24
2025-08-01PRTA-34.54-28.9211.24
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.12

Avg. EPS Est. Current Quarter

-1.79

Avg. EPS Est. Next Quarter

-0.88

Insider Transactions

-34.54

Institutional Transactions

-28.92

Beta

-0.03

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

23

Growth Score

39

Sentiment Score

47

Actual DrawDown %

91.5

Max Drawdown 5-Year %

-94.2

Target Price

24.29

P/E

Forward P/E

PEG

P/S

2.66

P/B

0.84

P/Free Cash Flow

EPS

-2.08

Average EPS Est. Cur. Y​

-4.54

EPS Next Y. (Est.)

-2.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-79.94

Relative Volume

0.48

Return on Equity vs Sector %

-48.9

Return on Equity vs Industry %

-30.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.86

EBIT Estimation

Prothena Corporation plc
Sector: Healthcare
Industry: Biotechnology
Employees: 163
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
stock quote shares PRTA -Prothena Corporation plc Stock Price stock today
news today PRTA -Prothena Corporation plc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRTA -Prothena Corporation plc yahoo finance google finance
stock history PRTA -Prothena Corporation plc invest stock market
stock prices PRTA premarket after hours
ticker PRTA fair value insiders trading